Bioequivalence of Biologics

Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development

Volumn , Issue , 2006, Pages 189-208

  Barrett, Jeffrey S ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Bioequivalence of biologics; Biotech drugs; Pharmaceutical equivalence; Pharmacodynamics; Pharmacokinetics; Prevailing opinion

Indexed keywords

EID: 78649383722     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527609628.ch8     Document Type: Chapter

References (39)

1. Nihalani P, Agrawal M, Anvekar A: Multisource biopharmaceuticals: a new perspective. Clin. Res. Reg. Affairs (2002) 19: 367-380.
2. IMSHealth.com. Biogenerics: a difficult birth? http://open.imshealth.com/webshop2/IMSinclude?I_article_20040518a.asp.
3. The Law of Biologic Medicine: Hearing Before the Subcommittee. on the Judiciary, 108th Cong. 1 (2004) (statement of Sen. Orrin Hatch, Chairman, Subcommittee. on the Judiciary).
4. Wasson A: Taking biologics for granted? Takings, trade secrets, and off-patent biological products. Duke Law & Technology Review (2005) Rev 0004 http://www.law.duke.edu/journals/dltr/articles/2005dltr0004.html.
5. Schellekens H, Ryff JC: 'Biogenerics': the off-patent biotech products. Trends Pharmacol. Sci. (2002) 23: 119-121.
6. Schellekens H: When biotech proteins go off-patent. Trends Biotechnol. (2004) 22: 406-410.
7. Biopharma: Biopharmaceutical products in the U.S. market. EPO/rDNA, Amgen. Biopharma.com. Available at: http://www.biopharma.com/sample_entries/118.html.
8. Committee for Proprietary Medicinal Products: Guideline on Comparability of Medicinal Products Containing Biotechnology-derived Proteins as Active Substance. Non-clinical and Clinical Issues. Evaluation of Medicines for Human Use, The European Agency for the Evaluation of Medicinal Products, London (2003).
9. Schellekens H, Casadevall N: Immunogenicity of recombinant human proteins: causes and consequences. J. Neurol. (2004) 251 (Suppl. 2): ii/4-ii/9.
10. Schellekens H: Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. (2002) 24 (11): 457-462.
11. Schellekens H: Biosimilar epoetins: how similar are they? Eur. J. Hosp. Pharm. (2004) 3: 43-47.
12. Haselbeck A: Epoetins: differences and their relevance to immunogenicity. Curr. Med. Res. Opin. (2003) 19: 430-432.
13. Boven K, Knight J, Bader F, Rossert J, Eckardt KU, Casadevall N: Epoetin associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol. Dial. Transplant. (2005) 20 (Suppl 3): iii33-iii40.
14. Schnabel CA, Fineberg SE, Kim DD: Immunogenicity of xenopeptide hormone therapies. Peptides (2006) 27 (7): 1902-1910.
15. Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S: Immunogenicity of recombinant human insulin. Diabetologia (1983) 25: 465-469.
16. Massa G, Vanderschueren-Lodeweyckx M, Bouillon R: Five year follow up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. Clin. Endocrinol. (1993) 38(2): 137-142.
17. Zeisel HJ, Lutz A, von Petrykowski W: Immunogenicity to mammalian cell derived recombinant growth hormone preparation during long term treatment. Hormone Res. (1992) 37 (Suppl 2): 47-55.
18. Rougeot C, Marchand P, Dray F, Girard F, Job JC, Pierson M, et al.: Comparative study of biosynthetic growth hormone immunogenicity in growth hormone deficient children. Hormone Res. (1991) 35(2): 78-81.
19. Anderson PJ: Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin. Arthritis Rheum. (2005) 34 (5 Suppl 11): 19-22.
20. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet (2002) 359: 1541-1549.
21. Figlin RA, Itri LM: Anti-Interferon antibodies: a perspective. Semin. Hematol. (1988) 25(3 Suppl 3): 9-15.
22. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations, U.S. Department of Health and Human Services, FDA (2002).
23. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, U.S. Department of Health and Human Services, FDA (2000).
24. Committee for Proprietary Medicinal Products: Guideline on Comparability of Medicinal Products Containing Biotechnology-derived Proteins as Active Substance. Quality Issues. Evaluation of Medicines for Human Use, The European Agency for the Evaluation of Medicinal Products, London (2003).
25. Committee for Proprietary Medicinal Products: Note for Guidance on Preclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals. Human Medicines Evaluation Unit, The European Agency for the Evaluation of Medicinal Products, London (1997).
26. Combe C, Tredree RL, Schellekens H: Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy (2005) 25(7): 954-962.
27. Maiorella BL, Ferris R, Thomson J, et al.: Evaluation of product equivalence during process optimization for manufacture of a human IgM monoclonal antibody. Biologicals (1993) 21: 197-205.
28. Barrett JS: Bioavailability and bioequivalence studies. In: Bonate PL, Howard DR (Eds.), Pharmacokinetics in Drug Development: Clinical Study Design and Analysis, Volume 1. AAPS Press, Arlington, VA (2004).
29. Patterson SD, Zariffa NM, Montague TH, Howland K: Nontraditional study designs to demonstrate average bioequivalence for highly variable drug products. Eur. J. Clin. Pharmacol. (2001) 57: 663-670.
30. Barrett JS, Kornhauser DH, Hainer JW, Gaskill J, Hua TA, Strogel P, Johansen K, van Lier JJ, Knebel W, Pieniaszek HJ: Anticoagulant pharmacodynamics of tinzaparin following 175 IU/kg subcutaneous administration to healthy volunteers. Thromb. Res. (2001) 101: 243-254.
31. Abbate R, Gori AM, Farsi A, Attanasio M, Pepe G: Monitoring of low-molecularweight heparins in cardiovascular disease. Am. J. Cardiol. (1998) 82: 33L-36L.
32. Fareed J, Walenga JM, Hoppensteadt D, Huan X, Racanelli A: Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis (1988) 18 (Suppl 3): 3-15.
33. Capila I, Linhardt RJ: Heparin-protein interactions. Angew Chemie Int. Ed. (2002) 41: 390-412.
34. Verstraete M: Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs (1990) 40: 498-530.
35. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban J-P, Bosson J-L, Mottier D, Beau B: A comparison of low-molecularweight heparin with unfractionated heparin for acute pulmonary embolism. N. Engl. J. Med. (1997) 337: 663-669.
36. Hirsch J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest (1998) 114: 489S-510S.
37. Barrett JS, Gibiansky E, Hull RD, Planès A, Pentikis H, Hainer JW, Hua TA, Gastonguay M: Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int. J. Clin. Pharmacol. Ther. (2001) 39(10): 431-446.
38. Laporte S, Mismetti P, Piquet P, Doubine S, Touchot A, Decousus H: Population pharmacokinetic of nadroparin calcium (Fraxiparine®) in children hospitalised for open heart surgery. Eur. J. Pharm. Sci. (1999) 8: 119-125.
39. Bara L, Planes A, Samama M-M: Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br. J. Haematol. (1999) 104: 230-240.